Register for updates

 
 

Medicine & Health
RSS Feed
TAU Researchers Discover Receptor Chain Involved in Atopic Dermatitis
Wednesday, February 19, 2020 10:12:00 AM

Researchers also formulate a novel antibody capable of blocking the development of the skin condition in mice

Atopic dermatitis, a chronic inflammatory disorder, affects some 30 million Americans every year. It is the most common cause of eczema, a condition marked by unbearably itchy, flaky patches of skin.

A new Tel Aviv University study identifies the precise receptor chain involved in the development of atopic dermatitis. The researchers hope to develop an antibody based on this research to create a therapeutic drug.

Research for the study was led by Prof. Ariel Munitz of the Department of Clinical Microbiology and Immunology at TAU's Sackler School of Medicine and Prof. Itai Benhar of the School of Molecular Cell Biology and Biotechnology at TAU's George S. Wise Faculty of Life Sciences and their PhD students Almog Bitton and Shmuel Avlas. It was published in Science Immunology on February 14.

"Atopic dermatitis is a serious, chronic condition that is usually detected in childhood. It's also associated with the development of such allergic diseases as asthma," Prof. Munitz explains. "We have now identified the chain of receptors involved in the pathology of this chronic condition that places such a burden on so many millions of people, not to mention health systems worldwide."

The clinical symptoms of atopic dermatitis are caused by two proteins, which are associated with multiple allergic diseases: interleukin 4 (IL-4) and interleukin 13 (IL-13). "The role of these proteins is so important that many pharmaceutical companies have targeted them for drug development for atopic dermatitis and for asthma," Prof. Munitz says. "In fact, recently the FDA has approved the use of an anti-IL-4 receptor antibody for the treatment of this condition."

While IL-4 and IL-13 mediate atopic dermatitis, the precise contribution of each of these proteins to the development of the disease was unknown. Both proteins use a complicated, often overlapping and complex set of receptors to mediate their activities.

In an attempt to better understand the pathology of atopic dermatitis and to identify new drug targets for treatment of the condition, the TAU researchers set out to identify the precise contribution of IL-4 versus that of IL-13 in atopic dermatitis. To do so, they harnessed mouse models that lacked the specific receptor chain: IL-13 receptor α 1, as well as various preclinical mouse models of atopic dermatitis.

"We identified that the IL-13 receptor alpha chain plays a critical role in atopic dermatitis," Prof. Benhar says. "In fact, we show that IL-13Rα1 mice that lack the IL-13 receptor α 1 do not develop the disease at all.

"Finally, we showed that a newly generated antibody was capable of reducing atopic dermatitis in mice. To translate our findings into human atopic dermatitis, we generated a novel antibody targeting the human IL-13 receptor α 1 and demonstrated that this antibody may serve as a prototype to treat the disease as well as other allergic diseases such as asthma or eosinophilic esophagitis," Prof. Benhar concludes.

See the publication at the Science Immunology web site here.




Latest News

Milner Foundation Donates $3 Million to Magen David Adom, TAU and Tel Aviv Sourasky Medical Center (Ichilov)

This "critical injection of oxygen" is expected to increase coronavirus remote testing and research.

New Sleep Method Strengthens Brain’s Ability to Retain Memories

Process that uses smell can strengthen memories stored in one side of the brain, say TAU, Weizmann researchers.

High Blood Pressure in Young Adulthood Associated With Cognitive Decline and Gait Impairment in Middle Age

TAU, Northwestern University study follows the blood pressure of dozens of people over a 30-year period.

TAU Researchers Discover Unique Non-Oxygen Breathing Animal

The tiny relative of the jellyfish is parasitic and dwells in salmon tissue.

TAU Researchers Discover Receptor Chain Involved in Atopic Dermatitis

Researchers also formulate a novel antibody capable of blocking the development of the skin condition in mice.

Disease Found in Fossilized Dinosaur Tail Afflicts Humans To This Day

The rare disease LCH discovered in the remains of a dinosaur that lived in Canada at least 60 million years ago, TAU researchers say.

TAU Researchers Demonstrate Optical Backflow of Light

"Abnormal" behavior predicted more than 50 years ago may help scientists probe the atmosphere and gauge the environment.

Induced Flaws in Metamaterials Can Produce Useful Textures and Behavior

Discovery advances the understanding of structural defects and their topological properties, TAU researchers say.

Iron Age Temple Complex Discovered Near Jerusalem Calls Into Question Biblical Depiction of Centralized Cult

Tel Moẓa site proves there were other sanctioned temples besides the official temple in Jerusalem, TAU researchers say.

contentSecondary
c

© 2020 American Friends of Tel Aviv University
39 Broadway, Suite 1510 | New York, NY 10006 | 212.742.9070 | info@aftau.org
Privacy policy | Tel Aviv University